DOTA‐NOC, A high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy
- 1 May 2001
- journal article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 44 (S1), S697-S699
- https://doi.org/10.1002/jlcr.25804401246
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Receptor Targeting for Tumor Localisation and Therapy with RadiopeptidesCurrent Medicinal Chemistry, 2000
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Yttrium-90 DOTATOC: first clinical resultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Tumour uptake of the radiolabelled somatostatin analogue [DOTA 0 ,TYR 3 ]octreotide is dependent on the peptide amountEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999